Predicting LDL-cholesterol reduction variability on statin–ezetimibe therapy: insights from “Jena auf Ziel”
View Full Paper
Ask AI
Bookmark
Share
Key result
Upfront atorvastatin and ezetimibe cuts LDL-C by ~65% regardless of baseline cholesterol metabolism markers.
- n=42
Why the study?
To assess individual variations in LDL-C response and investigate associations between baseline plasma surrogate markers of cholesterol metabolism and LDL-C reductions on combined lipid-lowering therapy.
Does atorvastatin and ezetimibe combination therapy reduce LDL-C consistently across different baseline cholesterol metabolism phenotypes in patients with STEMI?
Study Design
Type
Cohort (n=42)
Multicenter
No
Structured PICO
Does atorvastatin and ezetimibe combination therapy reduce LDL-C consistently across different baseline cholesterol metabolism phenotypes in patients with STEMI?
P
Population
42 lipid-lowering therapy-naïve patients with ST-elevation myocardial infarction treated with upfront combination therapy and followed for 6 weeks.
I
Intervention
Atorvastatin 80 mg and ezetimibe 10 mg initiated on admission for 4-6 weeks
O
Outcome
LDL-C reduction from baseline and its association with baseline plasma surrogate markers of cholesterol metabolism (absorption and synthesis) after 4-6 weekssurrogate
Upfront dual therapy with atorvastatin and ezetimibe in STEMI patients achieves robust LDL-C reduction with low interindividual variability, regardless of baseline cholesterol metabolism markers.
Limitations
- Small sample size which may have limited statistical power
- Secondary analysis without prior power calculations
- Only evaluated short-term response to treatment
- Observational study without a control group
- small sample size
- short-term response evaluation
- observational study with no control group
- secondary analysis without prior power calculations
Ask about this paper
Answers are grounded in this paper and cite their sources.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Through early combination therapy with a high-dose statin and ezetimibe, and an escalation of the lipid-lowering therapy with either bempedoic acid or PCSK9 inhibitors, potentially all STEMI patients can achieve the target LDL cholesterol levels recommended by the ESC/EAS without any significant side effects.”
Implication
May support upfront dual statin-ezetimibe in STEMI for consistent LDL-C lowering; hypothesis-generating on independence from metabolism markers, needing RCT confirmation.
Abstract
Background and aims Low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD). ESC/EAS guidelines recommend reducing LDL-C < 1.4 mmol/L and > 50% from baseline in patients with myocardial infarction. “Jena auf Ziel” (JaZ) is a prospective cohort study in which early combination therapy with atorvastatin 80 mg and ezetimibe 10 mg was initiated on admission in patients with ST-elevation myocardial infarction (STEMI) to reduce LDL‑C levels early and effectively. Methods In this secondary analysis, we included 42 patients who were naïve to lipid-lowering therapy (LLT) on admission. Aim of the current analysis was to assess individual variations in LDL‑C response and to investigate the associations between plasma surrogate markers of cholesterol metabolism at baseline and LDL‑C reductions after 4–6 weeks on combined LLT. Results Combined LLT with atorvastatin 80 mg and ezetimibe 10 mg reduced LDL‑C after 6 weeks in all patients very effectively (47.7–92.5%) across all quartiles of cholesterol absorption and synthesis markers. No statistically significant differences in LDL‑C reduction were observed across quartiles of cholesterol metabolism markers, although Pearson correlation analysis indicated a modest association between sitosterol:cholesterol and LDL‑C response. The median LDL‑C reduction was > 60% in all quartiles of cholesterol absorption (sitosterol:cholesterol, campesterol:cholesterol, cholestanol:cholesterol) and synthesis markers (lathosterol:cholesterol). We found no statistically significant differences regarding the LDL‑C change from baseline (%) in quartiles of sitosterol:cholesterol, campesterol:cholesterol, cholestanol:cholesterol (markers of cholesterol absorption), and lathosterol:cholesterol (marker of cholesterol synthesis). However, Pearson correlation values indicated a correlation between sitosterol:cholesterol and LDL‑C reduction with higher ratios being associated with less pronounced LDL‑C reduction. Conclusion Upfront dual therapy with atorvastatin (80 mg) and ezetimibe (10 mg) achieved robust LDL‑C reduction with low interindividual variability in treatment-naive individuals. We found no significant association between baseline cholesterol metabolism markers and treatment response. This supports current guideline recommendations for immediate combination therapy in very high-risk patients, irrespective of their baseline metabolic phenotype.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Makhmudova et al. (2026) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=42). Atorvastatin and ezetimibe was evaluated on LDL-C reduction from baseline. Upfront dual therapy with atorvastatin 80mg and ezetimibe 10mg achieved a median LDL-C reduction of 65.28% with no significant association between baseline cholesterol metabolism markers and treatment response.
View Full Paper
Ask AI
Bookmark
Share